SPC News Staff
FDA Halts MM Trial, Deaths Seen in Venclexta Arm
The FDA halted a clinical trial of Venclexta for MM because of an increased risk for death; does not affect ...
MARCH 22, 2019
FDA Approves Crysvita for Rare Rickets
The FDA approved Crysvita, the first drug indicated for adults and children aged 1 year and older with X-linked ...
APRIL 18, 2018
Trisenox Receives Indication for First-Line Treatment of APL
The FDA has approved the use of Trisenox injection used with tretinoin to treat adults with newly diagnosed ...
JANUARY 18, 2018
Updated Guidelines Expected to Clarify CF Diagnosis, Treatment
New CF guidelines will help clinicians to more accurately diagnose patients with symptoms of the disease and ...
FEBRUARY 10, 2017
Elevated Cataract Risk Seen in Some PCSK9-Treated Patients
PCSK9 inhibitors can reduce a high percentage of LDL cholesterol in high-risk patients, but there have been some ...
FEBRUARY 1, 2017
Those With HIV at Higher Risk for Diabetes
The prevalence of diabetes was nearly 4% higher among HIV patients than among the U.S. general public, and often in ...
JANUARY 31, 2017
New Indication Granted for Adynovate
Adynovate can now be used for children younger than 12 years of age.
DECEMBER 27, 2016
FDA Approves First Drug for Spinal Muscular Atrophy
Spinraza improved motor function in SMA patients; a greater percentage of infantile-onset patients survived.
DECEMBER 27, 2016
Study Could Explain Vulnerability of Young Cancer Patients to Treatment Toxicities
Young children remain at high risk for developing severe, long-lasting impairments in their brain, heart, and ...
DECEMBER 23, 2016
FDA Approves Rubraca for Advanced Ovarian Cancer
This is the first and only PARP inhibitor in the U.S. indicated to treat advanced ovarian cancer patients who have ...
DECEMBER 19, 2016
FDA Gives New Indication for Darzalex With 2 Standard Treatments for MM
Daratumumab induces tumor cell death through multiple immune-mediated mechanisms of action, including ...
NOVEMBER 22, 2016
FDA Approves Lartruvo for Advanced Soft Tissue Sarcoma
Lartruvo is the first FDA-approved front-line therapy for soft tissue sarcoma in four decades.
OCTOBER 20, 2016